# Life-insurance agentic workflow opportunities

## Recommendation

Build an **underwriting evidence-exception orchestrator**. The hero moment is an
underwriter reviewing a grounded recommendation that reconciles an application,
medical evidence, and third-party risk signals, then returning an authoritative
decision to a Flow that safely completes the case.

This is a sector-level recommendation, not a claim about one carrier's operation.
It is based on public U.S. evidence available on August 10, 2026. No internal
workflow, volume, automation inventory, or proven UiPath replication model was
available, so no internal ROI or delivery estimate is asserted.

## Evidence and operating context

- Underwriting combines application data with medical and other external
  evidence. NAIC describes traditional underwriting as requiring extensive
  medical information, often including an exam and fluid testing, while current
  regulatory work focuses on external data, predictive models, and possible
  unfair discrimination. Affected actors are applicants, producers, case
  managers, underwriters, medical-evidence vendors, and compliance/model-risk
  teams. ([NAIC, Accelerated Underwriting, updated 2025–2026](https://content.naic.org/insurance-topics/accelerated-underwriting))
- In a 2020 U.S./Canadian carrier study, LIMRA reported that automated or
  accelerated programs reached a final decision in 9 days on average versus 27
  days for traditional underwriting; 82% of respondents believed the programs
  reduced policy-issue time. This dated benchmark establishes material workflow
  potential, but is not a target or expected result for this demo. A carrier must
  establish its own baseline. ([LIMRA, 2020](https://www.limra.com/en/newsroom/industry-trends/2020/life-insurers-look-to-make-the-underwriting-process-easier-for-customers/))
- Human accountability remains integral. In the NAIC life-insurer AI/ML survey,
  respondents described straight-through cases, referrals with a suggested risk
  class, human review of potential adverse decisions, and underwriter overrides.
  This supports augmentation and exception routing, not autonomous adverse
  decisions. ([NAIC, *Life Insurance Artificial Intelligence/Machine Learning Survey Results*, pp. 135–137](https://content.naic.org/sites/default/files/inline-files/life-ai-survey-report-final.pdf))
- The scale and consequence of post-issue work are also substantial. ACLI's 2025
  Fact Book, based mainly on 2024 NAIC statutory data, reports $89 billion paid
  to life-insurance beneficiaries in 2024; it also reports $269 million in new
  claims plus $528 million in other claims in dispute, with $243 million still
  resisted at year end. Claims examiners, beneficiary-service teams, fraud/SIU,
  legal, and compliance therefore need complete evidence and defensible decision
  records. ([ACLI, *2025 Life Insurers Fact Book*, pp. xiii and 89–90](https://www.acli.com/-/media/public/pdf/news-and-analysis/publications-and-research/2025fb/all_acli_fact_book_2025.pdf))
- Unclaimed benefits create a distinct matching and outreach workflow. Through
  August 31, 2024, the NAIC policy locator had received 886,727 requests, produced
  460,952 policy or annuity matches, and connected consumers with $10.1 billion;
  a search may take 90 business days or more. Participating carriers must inspect
  secure requests, match policy data, contact beneficiaries, and report matches
  to regulators. ([NAIC, 2024](https://content.naic.org/article/naic-life-insurance-tool-helps-connect-consumers-more-10-billion-unclaimed-benefits))
- In-force service is another high-volume control point. ACLI reports 134 million
  individual policies in force and a 5.8% voluntary termination rate in 2024;
  group voluntary lapses reached 5.1%. Policy-service, billing, retention, and
  producer teams must distinguish intentional surrender from remediable payment
  or service exceptions. ([ACLI, *2025 Life Insurers Fact Book*, pp. 89 and 95](https://www.acli.com/-/media/public/pdf/news-and-analysis/publications-and-research/2025fb/all_acli_fact_book_2025.pdf))
- Consumer-facing decisions supported by AI require governance. The NAIC model
  bulletin calls for a written AI-systems program, data lineage and quality,
  bias analysis, controls on automation, third-party oversight, monitoring, and
  documentation available for examination. It is guidance that states may adopt,
  not itself a model law or regulation. ([NAIC model bulletin](https://content.naic.org/sites/default/files/inline-files/2023-12-4%20Model%20Bulletin_Adopted_0.pdf), [NAIC adoption summary](https://content.naic.org/article/naic-members-approve-model-bulletin-use-ai-insurers))
- Medical-record disclosure for life-insurance coverage generally requires a
  valid, specific authorization from the individual to the HIPAA-covered provider.
  This makes consent scope, purpose, expiration, revocation, and evidence access
  visible workflow controls. ([HHS, HIPAA Privacy Rule summary](https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html))

## Ranked demo candidates

Scores are comparative design judgments, not industry measurements. Each
dimension is scored 1–5. The total weights demo value 40%, enterprise
credibility 35%, and demo feasibility 25%.

| Rank | Candidate and visible decision | Evidence and affected teams | Demo value | Enterprise credibility | Feasibility | Weighted total |
| --- | --- | --- | ---: | ---: | ---: | ---: |
| 1 | **Underwriting evidence-exception orchestration** — decide straight-through, request evidence, offer/rate, postpone, or refer for adverse review | 9-day versus 27-day final-decision benchmark; underwriters, new business, producers, applicants, compliance ([LIMRA](https://www.limra.com/en/newsroom/industry-trends/2020/life-insurers-look-to-make-the-underwriting-process-easier-for-customers/)) | 5 | 5 | 4 | **4.75** |
| 2 | **Death-claim evidence and beneficiary settlement** — determine payable, request information, escalate investigation, or deny | $89B paid and $797M of new/other claims in dispute in 2024; claims, beneficiary service, SIU, legal ([ACLI](https://www.acli.com/-/media/public/pdf/news-and-analysis/publications-and-research/2025fb/all_acli_fact_book_2025.pdf)) | 5 | 5 | 3 | **4.50** |
| 3 | **Unclaimed-policy match and beneficiary outreach** — confirm a match and authorized contact path | 886,727 requests, 460,952 matches, $10.1B connected, and 90+ business-day searches; policy locator, claims, beneficiary service, regulators ([NAIC](https://content.naic.org/article/naic-life-insurance-tool-helps-connect-consumers-more-10-billion-unclaimed-benefits)) | 4 | 5 | 3 | **4.10** |
| 4 | **Lapse-risk service exception** — recommend payment remediation, producer outreach, or no action | 134M individual policies in force and 5.8% voluntary termination rate in 2024; billing, service, retention, producers ([ACLI](https://www.acli.com/-/media/public/pdf/news-and-analysis/publications-and-research/2025fb/all_acli_fact_book_2025.pdf)) | 4 | 4 | 4 | **4.00** |

The first candidate wins because the Flow can visibly coordinate documents,
APIs, legacy UI, deterministic rules, agent reasoning, a consequential human
decision, parallel communication, and audit write-back. The inference is that
this actor contrast will demonstrate Maestro better than the narrower matching
or servicing candidates; it is not a sourced claim about carrier performance.

## Strongest candidate: underwriting evidence-exception orchestrator

### Scope and narrative

The demo begins when a substantially complete individual term-life application
enters new business. It ends with either a policy-admin work item for an approved
offer, a tracked evidence request, or an underwriter-authorized adverse outcome.
Pricing, actuarial model development, sales advice, payment collection, policy
delivery, and autonomous decline are out of scope.

The measurable proof is operational rather than financial: elapsed application-
to-decision time, time waiting for evidence, evidence re-request rate, percentage
routed straight through, percentage correctly referred for human review, human
override rate, and completeness of the audit record. All are instrumentation
fields whose baselines and targets remain to be supplied by a carrier.

### Input contract

| Input | Minimum contract | Classification and validation |
| --- | --- | --- |
| Application event | `applicationId`, `receivedAt`, `productCode`, `faceAmount`, `jurisdiction`, `producerId`, `channel` | Unique `applicationId` is the correlation/idempotency key; reject unsupported product or jurisdiction. |
| Applicant facts | `applicantId`, age, residency, tobacco answer, identity-match status, declared conditions and medications | Synthetic data only in the demo; sensitive PII/health data in production. Do not expose raw identifiers to an agent when a derived attribute suffices. |
| Authorization | signed status, scope, source types, signed/expiry timestamps, revocation status | Stop evidence acquisition when absent, expired, revoked, or outside scope. HHS requires specific authorization for provider disclosure to a life insurer. ([HHS](https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html)) |
| Documents | application PDF, questionnaire, lab or exam report, attending-physician statement when present | IXP extracts document type, key fields, source page, and confidence; malformed or low-confidence packets enter review. |
| External evidence | normalized prescription, motor-vehicle, prior-application, and medical-record summaries with provider, timestamp, consent basis, and retrieval status | Demo fixtures replace real vendors. Preserve provenance; distinguish `notFound`, `notAuthorized`, `timeout`, and `providerError`. |
| Carrier rules | versioned product eligibility, evidence requirements, referral thresholds, and underwriting guide excerpts | Approved, read-only context only; record rule/context version on every recommendation. |

### Output contract

```json
{
  "applicationId": "LI-UW-00042",
  "caseStatus": "HUMAN_REVIEW_COMPLETED",
  "route": "OFFER_WITH_RATING",
  "proposedRiskClass": "TABLE_B",
  "finalRiskClass": "TABLE_C",
  "requiredEvidence": [],
  "evidenceFindings": [
    {
      "findingCode": "DECLARATION_MEDICATION_MISMATCH",
      "sourceRef": "rx-fixture-42",
      "ruleRef": "UW-GUIDE-2026.3#4.2",
      "severity": "REVIEW"
    }
  ],
  "recommendationRationale": "Structured, citation-backed summary",
  "confidence": 0.91,
  "humanDecision": {
    "outcome": "APPROVE_EDITED",
    "reviewerRole": "Senior Underwriter",
    "reasonCode": "ADDITIONAL_CONTEXT",
    "rationale": "Required reviewer rationale"
  },
  "communications": [{"type": "PRODUCER_STATUS", "status": "DRAFTED"}],
  "audit": {
    "rulesVersion": "UW-GUIDE-2026.3",
    "modelVersion": "demo-model-version",
    "startedAt": "ISO-8601",
    "completedAt": "ISO-8601",
    "traceId": "trace-id"
  }
}
```

`DECLINE`, `POSTPONE`, and any unresolved material inconsistency require a human
decision. The agent may recommend but cannot bind coverage, set final premium,
or author an adverse notice without review. The output persists the difference
between proposed and final fields so overrides are auditable.

### Reference-pattern mapping

| Reference segment | Life-insurance canvas segment | Actors and route |
| --- | --- | --- |
| Receive and understand | **1. Receive and validate application** | Application trigger; API workflow normalizes the event; IXP classifies/extracts the packet. Invalid consent or low confidence routes below the happy path. |
| Assess and enrich | **2. Gather and reconcile evidence** | API workflow calls synthetic evidence endpoints; RPA reads a mock legacy prescription-report portal; inline agent compares evidence with grounded underwriting rules; coded agent produces a compact, cited medical-record chronology. |
| Decide and review | **3. Recommend and underwrite** | Deterministic decision routes eligible clean cases, incomplete cases, and review cases. A coded action app shows discrepancies, source excerpts, rule citations, confidence, and the recommendation to a senior underwriter. |
| Act and communicate | **4. Record and notify** | After approval, parallel branches update a mock policy-admin UI through RPA and draft applicant/producer status through the coded agent; an API workflow writes the audit record. Branches merge before completion. Adverse routes produce a reviewed, reason-coded communication work item. |

Use four named sticky notes with a consistent left-to-right happy path and
exceptions below. The primary business expressions should use consent validity,
extraction confidence, evidence completeness, material inconsistency, and human
outcome—not hard-coded booleans.

### Integrations and demo mocks

| Dependency | Intended responsibility | Demo implementation | Failure path |
| --- | --- | --- | --- |
| New-business/application API | Trigger and canonical application status | Local fixture-backed API workflow | Duplicate event is idempotent; schema failure creates intake exception. |
| IXP | Application and medical-document classification/extraction | Synthetic PDFs and a purpose-built extraction project | Low confidence or missing required field goes to evidence review. |
| Prescription, MVR, MIB/prior-application, and EHR vendors | Risk evidence | Contract-shaped JSON fixtures; no vendor marks or claim of vendor connectivity | Per-source timeout/error status; continue only if product rules allow, otherwise request evidence. |
| Underwriting manual/context index | Ground recommendation in approved carrier rules | Synthetic guide with versioned passages | No supporting rule citation forces human review. |
| Legacy policy administration | Create offer work item and save final risk class | Local mock web app operated by RPA to make UI automation purposeful | Capture screenshot/error and queue manual write-back; never report completion. |
| Action Center coded action app | Senior-underwriter decision | Independently deployed review experience | Timeout escalates to underwriting queue; Flow resumes only from a valid named outcome. |
| Audit store | Case state, evidence lineage, prompts/outputs, rule/model versions, and decisions | Demo JSON or queue record; production system remains undecided | Write failure blocks completion and creates an operations incident. |

No UiPath tenant resource was verified during research. The local CLI is version
1.198.0, but `uip user` reported `authentication_required`; IXP, Action Center,
connections, folder placement, models, and policy-admin access are therefore
design dependencies, not ready resources.

### Human decisions

The senior underwriter sees identity and application facts, consent state,
extracted fields with source pages, cross-source discrepancies, missing evidence,
the versioned rule citations, agent recommendation and confidence, and previous
case actions. They may edit the proposed risk class and evidence list.

Named outcomes are `Approve`, `Approve edited`, `Request evidence`, `Postpone`,
`Decline`, and `Escalate`. Every outcome requires a reason code; edits, postpones,
declines, and escalations require free-text rationale. `Decline` and `Postpone`
route to a second-person or carrier-defined adverse-action control before any
customer communication. Timeout routes to an underwriting supervisor queue and
does not change coverage status.

### Risk, compliance, and operational controls

| Risk | Required control and visible evidence |
| --- | --- |
| Unsupported or unfair adverse outcome | No autonomous decline/postpone; approved rules and source citations; protected-class data segregated from case decisioning and used only for governed fairness testing where permitted; human override captured; pre-release and periodic outcome testing. NAIC expects accuracy, fairness, governance, and bias controls for AI-supported consumer decisions. ([NAIC](https://content.naic.org/sites/default/files/inline-files/2023-12-4%20Model%20Bulletin_Adopted_0.pdf)) |
| Medical-data overreach | Validate authorization before collection, disclose only scoped sources/fields, redact synthetic documents in screenshots, encrypt in transit/at rest, restrict access by role, and apply a configured retention schedule. ([HHS](https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html)) |
| Hallucinated evidence or rule | Agent output must use structured finding codes and resolvable `sourceRef`/`ruleRef`; absent citations force review; deterministic code validates allowed enums and thresholds. |
| Third-party model/data failure | Record vendor, version, timestamp, consent basis, and response status; apply contract-specific timeout/retry; no silent substitution; vendor/model changes require governed revalidation. |
| Lost or duplicated work | `applicationId` idempotency, explicit state transitions, retry-safe writes, human-task timeout, operations incident path, and merge only after both completion branches report success. |
| Inadequate explanation | Persist inputs used, rule/model versions, recommendation, confidence, reviewer changes, rationale, and final communication. Raw chain-of-thought is neither requested nor stored. |

### Evaluation and measurable outcomes

Use a synthetic set named `life-insurance-underwriting-exceptions-v1`:

| Case | Expected route and proof |
| --- | --- |
| Clean, authorized, complete case | Straight-through eligibility route; all required sources and rule citations present; offer work item and status draft complete. |
| Medication discrepancy | Human review; mismatch cites the prescription fixture and guide rule; edited decision persists. |
| Expired authorization | Stop before external evidence calls; request valid authorization; no medical fixture accessed. |
| Low-confidence physician statement | Evidence review; source page visible; no adverse recommendation. |
| Prescription endpoint timeout | Rule-driven fallback or evidence request; no fabricated `notFound`; audit records the timeout. |

Evaluate exact schema/enums, expected route, citation resolvability, absence of
unauthorized tool calls, required human review for adverse outcomes, RPA/API
completion before merge, and persisted audit fields. Capture operational measures
listed under scope, but set targets only after a carrier supplies baseline data.

## Unresolved assumptions for human review

1. Confirm the target carrier, country/state scope, individual versus group line,
   product, face-amount band, and actual underwriting authority matrix.
2. Choose the canonical application and audit systems, schemas, retention rules,
   and owners; decide whether this demo is one of the three Data Fabric/process-
   app variants.
3. Supply approved underwriting rules, permitted evidence sources, materiality
   thresholds, confidence thresholds, and exact routes eligible for straight-
   through processing.
4. Obtain legal, privacy, compliance, model-risk, and security approval for each
   data element, authorization form, model, prompt, log, and reviewer view in the
   intended jurisdictions.
5. Confirm whether MIB, prescription, MVR, EHR, and policy-admin sandboxes exist.
   Until then, use clearly labeled synthetic fixtures and the local mock UI.
6. Verify UiPath Labs `Playground` access under `JD_Demos/demos`, IXP/model resources,
   Action Center/action-app deployment, Integration Service connections, and the
   allowed model. The research session was not authenticated to UiPath.
7. Establish current baselines and acceptance targets for cycle time, evidence
   waits/re-requests, straight-through routing, referrals, overrides, errors,
   fairness monitoring, and audit completeness. Do not reuse LIMRA's 2020 carrier
   benchmark as the demo's promised result.
8. Decide who owns timeout escalation, adverse-outcome second review, notices,
   source-data disputes, model incidents, and post-deployment monitoring.

## Research method and limitations

This was a focused public-research scan of regulator, government, and industry-
association sources. It mapped observable sector evidence to the repository's
reference Flow topology and ranked four bounded opportunities. It did not mine
employee behavior, inspect a carrier's systems, identify single points of failure,
or find an existing internal automation to replicate. Source metrics describe the
U.S. market or surveyed carriers and must not be treated as one carrier's volume,
performance, savings, or ROI. The 2020 LIMRA cycle-time study is retained because
it provides a direct process benchmark; its age is a confidence limitation.
